Skip Navigation



Nucleic Acids Research Advance Access published online on July 7, 2009

Nucleic Acids Research, doi:10.1093/nar/gkp548
This Article
Right arrow Full Text Freely available
Right arrow Print PDF (541K) Freely available
Right arrow Screen PDF (4301K) Freely available
Right arrow Supplementary Data
Right arrowOA All Versions of this Article:
37/16/5405    most recent
gkp548v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Grizot, S.
Right arrow Articles by Duchateau, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grizot, S.
Right arrow Articles by Duchateau, P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2009 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Nucleic Acid Enzymes

Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease

Sylvestre Grizot1, Julianne Smith2, Fayza Daboussi1, Jesús Prieto3, Pilar Redondo3, Nekane Merino4, Maider Villate4, Séverine Thomas1, Laetitia Lemaire2, Guillermo Montoya3, Francisco J. Blanco4, Frédéric Pâques1,2,* and Philippe Duchateau1

1Cellectis S.A., 2Cellectis Genome Surgery, 102 Avenue Gustave Roussel, 93235 Romainville, France, 3Structural Biology and Biocomputing Program, Spanish National Cancer Center (CNIO), Macromolecular Crystallography Group, Melchor Fdez. Almagro 3, 28029 Madrid and 4Structural Biology Unit, CIC bioGUNE, Parque Tecnológico de Vizcaya, Edificio 800 48160, Derio, Spain

*To whom correspondence should be addressed. Tel: 33 1 41 83 99 14; Fax: 33 1 41 83 99 03; Email: paques{at}cellectis.com The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.

Received May 5, 2009. Revised June 10, 2009. Accepted June 11, 2009.

Sequence-specific endonucleases recognizing long target sequences are emerging as powerful tools for genome engineering. These endonucleases could be used to correct deleterious mutations or to inactivate viruses, in a new approach to molecular medicine. However, such applications are highly demanding in terms of safety. Mutations in the human RAG1 gene cause severe combined immunodeficiency (SCID). Using the I-CreI dimeric LAGLIDADG meganuclease as a scaffold, we describe here the engineering of a series of endonucleases cleaving the human RAG1 gene, including obligate heterodimers and single-chain molecules. We show that a novel single-chain design, in which two different monomers are linked to form a single molecule, can induce high levels of recombination while safeguarding more effectively against potential genotoxicity. We provide here the first demonstration that an engineered meganuclease can induce targeted recombination at an endogenous locus in up to 6% of transfected human cells. These properties rank this new generation of endonucleases among the best molecular scissors available for genome surgery strategies, potentially avoiding the deleterious effects of previous gene therapy approaches.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.